- Dose Finding and Early Efficacy Study of Gemcitabine Plus Capecitabine in Combination With Bevacizumab Plus Erlotinib in Advanced Pancreatic Cancer
[作者：Starling, N; Watkins, D; Cunningham, D; Thomas, J; Webb, J; Brown, G; Thomas, K; Oates, J; Chau, I,期刊：Journal of clinical oncology, 页码：5499-5505 , 文章类型： Article，,卷期：2009年27-33]
- Purpose This study evaluated safety and efficacy of chemotherapy (gemcitabine plus capecitabine) plus bevacizumab/erlotinib in advanced pancreatic cancer because dual epidermal growth factor receptor/vascular endothelial...
- Randomized Phase II Study of Gemcitabine Administered at a Fixed Dose Rate or in Combination With Cisplatin, Docetaxel, or Irinotecan in Patients With Metastatic Pancreatic Cancer: CALGB 89904
[作者：Kulke, MH; Tempero, MA; Niedzwiecki, D; Hollis, DR; Kindler, HL; Cusnir, M; Enzinger, PC; Gorsch, SM; Goldberg, RM; Mayer, RJ,期刊：Journal of clinical oncology, 页码：5506-5512 , 文章类型： Article，,卷期：2009年27-33]
- Purpose The relative value of gemcitabine-based combination chemotherapy therapy and prolonged infusions of gemcitabine in patients with advanced pancreatic cancer remains controversial. We explored the efficacy and toxi...
- Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
[作者：Cunningham, D; Chau, I; Stocken, DD; Valle, JW; Smith, D; Steward, W; Harper, PG; Dunn, J; Tudur-Smith, C; West, J; Falk, S; Crellin, A; Adab, F; Thompson, J; Leonard, P; Ostrowski, J; Eatock, M; Scheithauer, W; Herrmann, R; Neoptolemos, JP,期刊：Journal of clinical oncology, 页码：5513-5518 , 文章类型： Article，,卷期：2009年27-33]
- Purpose Both gemcitabine (GEM) and fluoropyrimidines are valuable treatment for advanced pancreatic cancer. This open-label study was designed to compare the overall survival (OS) of patients randomly assigned to GEM alo...
- Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS Trial
[作者：Braun, MS; Richman, SD; Thompson, L; Daly, CL; Meade, AM; Adlard, JW; Allan, JM; Parmar, MKB; Quirke, P; Seymour, MT,期刊：Journal of clinical oncology, 页码：5519-5528 , 文章类型： Article，,卷期：2009年27-33]
- Purpose Predicting efficacy and toxicity could potentially allow individualization of cancer therapy. We investigated putative pharmacogenetic markers of chemotherapy toxicity in a large randomized trial. Patients, Mater...
- Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
[作者：Kaufman, B; Mackey, JR; Clemens, MR; Bapsy, PP; Vaid, A; Wardley, A; Tjulandin, S; Jahn, M; Lehle, M; Feyereislova, A; Revil, C; Jones, A,期刊：Journal of clinical oncology, 页码：5529-5537 , 文章类型： Article，,卷期：2009年27-33]
- Purpose TAnDEM is the first randomized phase III study to combine a hormonal agent and trastuzumab without chemotherapy as treatment for human epidermal growth factor receptor 2 (HER2)/hormone receptor-copositive metasta...
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
[作者：Johnston, S; Pippen, J; Pivot, X; Lichinitser, M; Sadeghi, S; Dieras, V; Gomez, HL; Romieu, G; Manikhas, A; Kennedy, MJ; Press, MF; Maltzman, J; Florance, A; O'Rourke, L; Oliva, C; Stein, S; Pegram, M,期刊：Journal of clinical oncology, 页码：5538-5546 , 文章类型： Article，,卷期：2009年27-33]
- Purpose Cross-talk between human epidermal growth factor receptors and hormone receptor pathways may cause endocrine resistance in breast cancer. This trial evaluated the effect of adding lapatinib, a dual tyrosine kinas...
- Extensive Nodal Disease May Impair Axillary Reverse Mapping in Patients With Breast Cancer
[作者：Ponzone, R; Cont, NT; Maggiorotto, F; Cassina, E; Mininanni, P; Biglia, N; Sismondi, P,期刊：Journal of clinical oncology, 页码：5547-5551 , 文章类型： Article，,卷期：2009年27-33]
- Purpose The aim of axillary reverse mapping (ARM) is to preserve arm lymphatics in patients with breast cancer who underwent surgical axillary staging. Patients and Methods From June 2007 to December 2008, 49 patients wh...
- Prognostic and Predictive Value of HER2 Extracellular Domain in Metastatic Breast Cancer Treated With Lapatinib and Paclitaxel in a Randomized Phase III Study
[作者：Finn, RS; Gagnon, R; Di Leo, A; Press, MF; Arbushites, M; Koehler, M,期刊：Journal of clinical oncology, 页码：5552-5558 , 文章类型： Article，,卷期：2009年27-33]
- Purpose The HER2 extracellular domain (ECD) is enzymatically cleaved from the cell membrane. Shed ECD in serum has been studied as both prognostic and predictive markers. Lapatinib is a dual inhibitor of HER2 and epiderm...
- Racial Differences in Predictors of Intensive End-of-Life Care in Patients With Advanced Cancer
[作者：Loggers, ET; Maciejewski, PK; Paulk, E; DeSanto-Madeya, S; Nilsson, M; Viswanath, K; Wright, AA; Balboni, TA; Temel, J; Stieglitz, H; Block, S; Prigerson, HG,期刊：Journal of clinical oncology, 页码：5559-5564 , 文章类型： Article，,卷期：2009年27-33]
- Purpose Black patients are more likely than white patients to receive life-prolonging care near death. This study examined predictors of intensive end-of-life (EOL) care for black and white advanced cancer patients. Pati...
- Mobile Phone Use and Risk of Tumors: A Meta-Analysis
[作者：Myung, SK; Ju, W; McDonnell, DD; Lee, YJ; Kazinets, G; Cheng, CT; Moskowitz, JM,期刊：Journal of clinical oncology, 页码：5565-5572 , 文章类型： Article，,卷期：2009年27-33]
- Purpose Case-control studies have reported inconsistent findings regarding the association between mobile phone use and tumor risk. We investigated these associations using a meta-analysis. Methods We searched MEDLINE (P...
- Immuno-Fluorescence In Situ Hybridization Index Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A GELA Study
[作者：Copie-Bergman, C; Gaulard, P; Leroy, K; Briere, J; Baia, M; Jais, JP; Salles, GA; Berger, F; Haioun, C; Tilly, H; Emile, JF; Banham, AH; Mounier, N; Gisselbrecht, C; Feugier, P; Coiffier, B; Molina, TJ,期刊：Journal of clinical oncology, 页码：5573-5579 , 文章类型： Article，,卷期：2009年27-33]
- Purpose To evaluate the prognostic value of cell of origin immunohistochemical markers and BCL2, BCL6, and c-MYC translocations in a homogeneous cohort of patients with diffuse large B-cell lymphoma (DLBCL) treated with ...
- Age-Specific Differences in Oncogenic Pathway Dysregulation and Anthracycline Sensitivity in Patients With Acute Myeloid Leukemia
[作者：Rao, AV; Valk, PJM; Metzeler, KH; Acharya, CR; Tuchman, SA; Stevenson, MM; Rizzieri, DA; Delwel, R; Buske, C; Bohlander, SK; Potti, A; Lowenberg, B,期刊：Journal of clinical oncology, 页码：5580-5586 , 文章类型： Article，,卷期：2009年27-33]
- Purpose To define the biology driving the aggressive nature of acute myeloid leukemia (AML) in elderly patients. Patients and Methods Clinically annotated microarray data from 425 patients with newly diagnosed de novo AM...
|